Mulligan Deanna
Known title: DirectorCIK: 0001575663
Associated companies
Transaction History
| DD | ▲ Buy | Grant | 397 | $33K | 2/28/2025 | View on chart |
| DD | ▲ Buy | Grant | 389 | $33K | 11/29/2024 | View on chart |
| DD | ▲ Buy | Grant | 386 | $32K | 8/30/2024 | View on chart |
| DD | ▲ Buy | Grant | 2,109 | $0 | 6/5/2024 | View on chart |
| DD | ▲ Buy | Grant | 396 | $32K | 5/31/2024 | View on chart |
| DD | ▲ Buy | Grant | 470 | $33K | 2/29/2024 | View on chart |
| DD | ▲ Buy | Grant | 454 | $32K | 11/30/2023 | View on chart |
| DD | ▲ Buy | Grant | 423 | $32K | 8/31/2023 | View on chart |
| DD | ▲ Buy | Grant | 484 | $32K | 5/31/2023 | View on chart |
| DD | ▲ Buy | Grant | 2,566 | $0 | 5/24/2023 | View on chart |
| DD | ▲ Buy | Grant | 445 | $33K | 2/28/2023 | View on chart |
| DD | ▲ Buy | Grant | 461 | $32K | 11/30/2022 | View on chart |
| DD | ▲ Buy | Grant | 584 | $33K | 8/31/2022 | View on chart |
| DD | ▲ Buy | Grant | 1,000 | $0 | 8/4/2022 | View on chart |
| DD | ▲ Buy | Grant | 427 | $29K | 5/31/2022 | View on chart |
| DD | ▲ Buy | Grant | 2,524 | $170K | 5/26/2022 | View on chart |
| DD | ▲ Buy | Grant | 372 | $29K | 2/28/2022 | View on chart |
| DD | ▲ Buy | Grant | 389 | $29K | 11/30/2021 | View on chart |
| DD | ▲ Buy | Grant | 388 | $29K | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DuPont receives analyst upgrades and announces quarterly dividend
DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.
DuPont receives analyst upgrades and announces quarterly dividend. DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.